Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BIRT 2584 XX on PK of CYP Substrates
NCT02256813Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2005
- Primary completion
- Dec 2005
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of BIRT 2584 XX in psoriasis and rheumatoid arthritis (RA), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 extrapolated to infinity, Area under the concentration-time curve of the ratio of omeprazole to 5-hydroxyomeprazole and 2 more. Started Sep 2005; status: completed.
02
Drugs
BIRT 2584 XX
03
Conditions
psoriasisrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02256813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256813.